{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:51:59Z","timestamp":1757314319994,"version":"3.40.5"},"reference-count":41,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2021,1,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> The interactions between Alzheimer\u2019s Disease (AD) and major depression\ncan be translated into clinical data showing that depressive patients have had an enhanced risk for\ndeveloping AD (later in life). The cellular mechanisms involved in these interactions remain under\nintensive debate in the literature. In addition, the role of a Ca<jats:sup>2+<\/jats:sup> homeostasis dysregulation in the\npathogenesis of neurodegenerative diseases, like AD, and major depression has been under intensive\ndiscussion.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Thus, revealing the interplay between AD and major depression may provide novel insights\ninto the pathogenesis of these diseases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Publications involving Ca<jats:sup>2+<\/jats:sup> signalling pathways, AD, and major depression (alone or\ncombined) were collected by searching multiple databases to find the maximum number of relevant\ncitations (using a search strategy with high sensitivity for studies of etiology).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Ca<jats:sup>2+<\/jats:sup> Channel Blockers (CCBs), classically prescribed for hypertensive patients, have been\ndemonstrating neuroprotective effects, such as decreasing the incidence of AD in hypertensive patients,\nincluding alleviating major depression symptoms. A mechanism under debate is focused on the restoration\nof the Ca<jats:sup>2+<\/jats:sup> homeostasis. Indeed, previous studies of our own have correlated Ca<jats:sup>2+<\/jats:sup> and cAMP signalling\npathways (Ca<jats:sup>2+<\/jats:sup>\/cAMP signalling) in controlling both the neurotransmitter release and neuronal\ndeath. These studies also observed that CCBs can affect Ca<jats:sup>2+<\/jats:sup>\/cAMP signalling.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> This review discussed the plausible role of Ca<jats:sup>2+<\/jats:sup>\/cAMP signalling in the neuroprotective\neffects of CCBs, including the participation of Ca<jats:sup>2+<\/jats:sup>\/cAMP signalling in the interactions between\nmajor depression and AD. Considering both AD and major depression have become highly\nprevalent medical problems in the world, the comprehension of the interactions between these diseases\ncould improve drug development.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2589977512666200217093356","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T13:22:46Z","timestamp":1581945766000},"page":"97-102","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Interactions Between Alzheimer\u2019s Disease and Major Depression: Role of Ca2+ Channel Blockers and Ca2+\/cAMP Signalling"],"prefix":"10.2174","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7432-9958","authenticated-orcid":true,"given":"Leandro Bueno","family":"Bergantin","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de Sao Paulo; Rua Pedro de Toledo 669, Vila Clementino, Sao Paulo - SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/archpsyc.63.5.530","volume":"63","author":"Ownby R.L.","year":"2006","unstructured":"Ownby R.L.; Crocco E.; Acevedo A.; John V.; Loewenstein D.; Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006,63(5),530-538","journal-title":"Arch Gen Psychiatry"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ejphar.2016.06.034","volume":"788","author":"Bergantin L.B.","year":"2016","unstructured":"Bergantin L.B.; Caricati-Neto A.; Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca(2+)\/cAMP intracellular signalling interaction. Eur J Pharmacol 2016,788,255-260","journal-title":"Eur J Pharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ceca.2013.06.004","volume":"54","author":"Bergantin L.B.","year":"2013","unstructured":"Bergantin L.B.; Souza C.F.; Ferreira R.M.; Smaili S.S.; Jurkiewicz N.H.; Caricati-Neto A.; Novel model for \u201ccalcium paradox\u201d in sympathetic transmission of smooth muscles: role of cyclic AMP pathway. Cell Calcium 2013,54(3),202-212","journal-title":"Cell Calcium"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.4172\/2168-975X.1000e125","volume":"6","author":"Bergantin L.B.","year":"2017","unstructured":"Bergantin L.B.; Neurodegenerative Diseases: Where to go from now? Thought provoking through Ca2+\/cAMP signaling interaction. Brain Disord Ther 2017,6(04)","journal-title":"Brain Disord Ther"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.4172\/2329-6895.1000e124","volume":"5","author":"Bergantin L.B.","year":"2017","unstructured":"Bergantin L.B.; Neurological disorders: Is there a horizon? Emerging ideas from the interaction between Ca2+ and camp signaling pathways. J Neurol Disord 2017,5(6)","journal-title":"J Neurol Disord"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/prp2.181","volume":"3","author":"Caricati-Neto A.","year":"2015","unstructured":"Caricati-Neto A.; Garc\u00eda A.G.; Bergantin L.B.; Pharmacological implications of the Ca(2+)\/cAMP signaling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. Pharmacol Res Perspect 2015,3(5),181","journal-title":"Pharmacol Res Perspect"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.tins.2008.06.005","volume":"31","author":"Bezprozvanny I.","year":"2008","unstructured":"Bezprozvanny I.; Mattson M.P.; Neuronal calcium mishandling and the pathogenesis of Alzheimer\u2019s disease. Trends Neurosci 2008,31(9),454-463","journal-title":"Trends Neurosci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15761\/JSIN.1000185","author":"Caricati-Neto A.","year":"2017","unstructured":"Caricati-Neto A.; Bergantin L.B.; Pharmacological modulation of neural Ca2+\/camp signaling interaction as therapeutic goal for treatment of Alzheimer\u2019s disease. J Syst Integr Neurosci 2017,3","journal-title":"J Syst Integr Neurosci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15761\/JSIN.1000186","author":"Caricati-Neto A.","year":"2017","unstructured":"Caricati-Neto A.; Bergantin L.B.; The passion of a scientific discovery: the \u201ccalcium paradox\u201d due to Ca2+\/camp interaction. J Syst Integr Neurosci 2017,3","journal-title":"J Syst Integr Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.15761\/JSIN.1000187","volume":"4","author":"Caricati-Neto A.","year":"2018","unstructured":"Caricati-Neto A.; Bueno Bergantin L.; From a \u201ceureka insight\u201d to a novel potential therapeutic target to treat Parkinson\u2019s disease: The Ca2+\/camp signalling interaction. J Syst Integr Neurosci 2018,4(1)","journal-title":"J Syst Integr Neurosci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.23937\/2572-3987.1510007","volume":"2","author":"Bergantin L.B.","year":"2016","unstructured":"Bergantin L.B.; Caricati-Neto A.; Insight from \u201cCalcium Paradox\u201d due to Ca2+\/cAMP Interaction: Novel Pharmacological Strategies for the Treatment of Depression. Int Arch Clin Pharmacol 2016,2,7","journal-title":"Int Arch Clin Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004593","volume":"95","author":"Wu C.L.","year":"2016","unstructured":"Wu C.L.; Wen S.H.; A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients. Medicine 2016,95(32)","journal-title":"Medicine"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","volume":"350","author":"Staessen J.A.","year":"1997","unstructured":"Staessen J.A.; Fagard R.; Thijs L.; Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in europe (syst-eur) trial investigators. Lancet 1997,350(9080),757-764","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(98)03086-4","volume":"352","author":"Forette F.","year":"1998","unstructured":"Forette F.; Seux M.L.; Staessen J.A.; Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in europe (syst-eur) trial. Lancet 1998,352(9137),1347-1351","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/aje\/153.1.72","volume":"153","author":"Di Bari M.","year":"2001","unstructured":"Di Bari M.; Pahor M.; Franse L.V.; Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol 2001,153(1),72-78","journal-title":"Am J Epidemiol"},{"key":"ref=16","first-page":"13","volume":"3","author":"Bergantin L.B.","year":"2017","unstructured":"Bergantin L.B.; Caricati-Neto A.; Novel concepts for clinical pharmacology from \u201ccalcium paradox\u201d due to neuronal interaction between signalling pathways mediated by ca2+ and camp: from 1975 to 2017. Int Arch Clin Pharmacol 2017,3,13","journal-title":"Int Arch Clin Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.17756\/jnen.2017-024","volume":"3","author":"Bergantin L.B.","year":"2017","unstructured":"Bergantin L.B.; Caricati-Neto A.; Emerging concepts for neuroscience field from ca2+\/camp signalling interaction. J Neurol Exp Neurosci 2017,3(1),29-32","journal-title":"J Neurol Exp Neurosci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15761\/JSIN.1000161","author":"Bergantin L.B.","year":"2017","unstructured":"Bergantin L.B.; Advances for the pharmacotherapy of depression - Presenting the rising star: Ca2+\/camp signaling interaction. J Syst Integr Neurosci 2017,3","journal-title":"J Syst Integr Neurosci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1212\/WNL.41.9.1393","volume":"41","author":"Kokmen E.","year":"1991","unstructured":"Kokmen E.; Beard C.M.; Chandra V.; Offord K.P.; Schoenberg B.S.; Ballard D.J.; Clinical risk factors for Alzheimer\u2019s disease: A population-based case-control study. Neurolog 1991,41(9),1393-1397","journal-title":"Neurolog"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/00001648-199507000-00006","volume":"6","author":"Speck C.E.","year":"1995","unstructured":"Speck C.E.; Kukull W.A.; Brenner D.E.; History of depression as a risk factor for Alzheimer\u2019s disease. Epidemiology 1995,6(4),366-369","journal-title":"Epidemiology"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1017\/S104161029700447X","volume":"9","author":"Tsolaki M.","year":"1997","unstructured":"Tsolaki M.; Fountoulakis K.; Chantzi E.; Kazis A.; Risk factors for clinically diagnosed Alzheimer\u2019s disease: A case-control study of a Greek population. Int Psychogeriatr 1997,9(3),327-341","journal-title":"Int Psychogeriatr"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/archneur.60.5.753","volume":"60","author":"Green R.C.","year":"2003","unstructured":"Green R.C.; Cupples L.A.; Kurz A.; Auerbach S.; Go R.; Sadovnick D.; Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol 2003,60(5),753-759","journal-title":"Arch Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/01.STR.0000054050.51530.76","volume":"34","author":"Iadecola C.","year":"2003","unstructured":"Iadecola C.; Gorelick P.B.; Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003,34(2),335-337","journal-title":"Stroke"},{"key":"ref=24","first-page":"M178","volume":"59","author":"Rasgon N.","year":"2004","unstructured":"Rasgon N.; Jarvik L.; Insulin resistance, affective disorders, and Alzheimer\u2019s disease: Review and hypothesis. J Gerontol A Biol. Med Sci 2004,59,M178-M183","journal-title":"Med Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.amjcard.2004.07.127","volume":"94","author":"Parissis J.T.","year":"2004","unstructured":"Parissis J.T.; Adamopoulos S.; Rigas A.; Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol 2004,94(10),1326-1328","journal-title":"Am J Cardiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/sj.mp.4000572","volume":"4","author":"Dantzer R.","year":"1999","unstructured":"Dantzer R.; Wollman E.; Vitkovic L.; Yirmiya R.; Cytokines and depression: fortuitous or causative association? Mol Psychiatry 1999,4(4),328-332","journal-title":"Mol Psychiatry"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.psyneuen.2004.01.002","volume":"29","author":"Suarez E.C.","year":"2004","unstructured":"Suarez E.C.; Lewis J.G.; Krishnan R.R.; Young K.H.; Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinology 2004,29(9),1119-1128","journal-title":"Psychoneuroendocrinology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.crvi.2004.10.013","volume":"328","author":"St George-Hyslop P.H.","year":"2005","unstructured":"St George-Hyslop P.H.; Petit A.; Molecular biology and genetics of Alzheimer\u2019s disease. C R Biol 2005,328(2),119-130","journal-title":"C R Biol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.biopsych.2004.02.033","volume":"56","author":"Duman R.S.","year":"2004","unstructured":"Duman R.S.; Depression: A case of neuronal life and death? Biol Psychiatry 2004,56(3),140-145","journal-title":"Biol Psychiatry"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1113\/jphysiol.1961.sp006791 PMID: 13887557","volume":"159","author":"Douglas W.W.","year":"1961","unstructured":"Douglas W.W.; Rubin R.P.; The role of calcium in the secretory response of the adrenal medulla to acetylcholine. J Physiol 1961,159,40-57","journal-title":"J Physiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/276620a0","volume":"276","author":"Baker P.F.","year":"1978","unstructured":"Baker P.F.; Knight D.E.; Calcium-dependent exocytosis in bovine adrenal medullary cells with leaky plasma membranes. Nature 1978,276(5688),620-622","journal-title":"Nature"},{"key":"ref=32","first-page":"287","author":"Kreye V.A.","year":"1975","unstructured":"Kreye V.A.; L\u00fcth J.B.; Proceedings: Verapamil-induced phasic contractions of the isolated rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol 1975,287","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1476-5381.1981.tb10424.x PMID: 7236986","volume":"73","author":"French A.M.","year":"1981","unstructured":"French A.M.; Scott N.C.; A comparison of the effects of nifedipine and verapamil on rat vas deferens. Br J Pharmacol 1981,73(2),321-323","journal-title":"Br J Pharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0014-2999(87)90636-4","volume":"140","author":"Moritoki H.","year":"1987","unstructured":"Moritoki H.; Iwamoto T.; Kanaya J.; Maeshiba Y.; Ishida Y.; Fukuda H.; Verapamil enhances the non-adrenergic twitch response of rat vas deferens. Eur J Pharmacol 1987,140(1),75-83","journal-title":"Eur J Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nm0395-244","volume":"1","author":"Sommer N.","year":"1995","unstructured":"Sommer N.; L\u00f6schmann P.A.; Northoff G.H.; The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995,1(3),244-248","journal-title":"Nat Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1124\/jpet.111.179358","volume":"338","author":"Xiao L.","year":"2011","unstructured":"Xiao L.; O\u2019Callaghan J.P.; O\u2019Donnell J.M.; Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test. J Pharmacol Exp Ther 2011,338(2),641-647","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1017\/S1041610217002903","volume":"30","author":"Tully P.J.","year":"2018","unstructured":"Tully P.J.; Peters R.; P\u00e9r\u00e8s K.; Anstey K.J.; Tzourio C.; Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: three city cohort study. Int Psychogeriatr 2018,30(9),1345-1354","journal-title":"Int Psychogeriatr"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.phrs.2019.01.008","volume":"141","author":"Bergantin L.B.","year":"2019","unstructured":"Bergantin L.B.; Debating the \u201cbidirectional link\u201d between diabetes and depression through the Ca2+\/cAMP signalling: Off-label effects of Ca2+ channel blockers. Pharmacol Res 2019,141,298-302","journal-title":"Pharmacol Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/1573402114666180817113242","volume":"15","author":"Bergantin L.B.","year":"2019","unstructured":"Bergantin L.B.; Hypertension, diabetes and neurodegenerative diseases: is there a clinical link through the ca2+\/camp signalling interaction? Curr Hypertens Rev 2019,15(1),32-39","journal-title":"Curr Hypertens Rev"},{"key":"ref=40","author":"Bergantin L.","year":"2018","unstructured":"Bergantin L.; Caricati-Neto A.;  The \u201ccalcium paradox\u201d and its impact on neurological and psychiatric diseases 2018","journal-title":"The \u201ccalcium paradox\u201d and its impact on neurological and psychiatric diseases"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3233\/JAD-2012-120748","volume":"32","author":"Kennelly S.","year":"2012","unstructured":"Kennelly S.; Collins O.; Walking the cognitive \u201cMinefield\u201d between high and low blood pressure. J Alzheimers Dis 2012,32(3),609-621","journal-title":"J Alzheimers Dis"}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/179392\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/179392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T15:30:48Z","timestamp":1638804648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179392\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2589977512666200217093356","relation":{},"ISSN":["2589-9775"],"issn-type":[{"type":"print","value":"2589-9775"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}